Production & Manufacturing
Manufacturing

Aquestive settles Suboxone drug patent infringement case with Par Pharmaceuticals

Published 15 May 2018

Aquestive Therapeutics has reached a settlement agreement resolving patent litigation related to Suboxone (buprenorphine and naloxone) Sublingual Film with Par Pharmaceuticals.

Indivior PLC and its U.S. subsidiary, Indivior Inc., marketers and distributors of SUBOXONE, joined partner Aquestive in the settlement with Par Pharmaceuticals, Inc., an operating company of Endo International PLC and IntelGenx Technologies Corp.

Under the settlement agreement, Par Pharmaceuticals and IntelGenx agreed to launch their proposed generic version of the buprenorphine and naloxone sublingual film no earlier than January 1, 2023.

The patent-infringement litigation has been pending in the U.S. District Court for the District of Delaware. As required by law, the parties will submit the settlement agreement to the U.S. Federal Trade Commission and the U.S. Department of Justice for review. 

Aquestive CEO Keith Kendall said: "This settlement once again demonstrates the value our intellectual property and know-how represent for us and our partners.

"We will continue to focus our PharmFilm technology platform on innovating within difficult disease states such as epilepsy, Parkinson's and ALS."

Source: Company Press Release.